The PDUFA extension adds regulatory uncertainty but the EU positive opinion and pending ASCO data provide a potential catalyst on June 2, 2026. Traders should watch for the ASCO presentation and any subsequent FDA communication; the stock may remain range-bound until a new PDUFA date is announced.
Price Chart
Executive Summary
AstraZeneca announced the FDA extended the PDUFA date for camizestrant in HR+/HER2- advanced breast cancer to review additional data, including ctDNA clearance analyses to be presented at ASCO 2026. The FDA's advisory committee had previously failed to reach a majority vote in favor in April 2026, adding uncertainty; however, the EU's CHMP adopted a positive opinion on May 22, 2026, partially offsetting the delay. The extension introduces delay risk but is not a rejection, and the stock's historical negative drift on prior regulatory updates warrants a cautious view.
Key Facts
- FDA extended PDUFA date for camizestrant NDA (SERENA-6) to review additional data, including ctDNA clearance outcomes
- FDA's ODAC did not reach a majority vote in favor of the treatment strategy in April 2026
- EU's CHMP adopted a positive opinion recommending approval on May 22, 2026
- Camizestrant already approved in UAE and Saudi Arabia; regulatory reviews ongoing in Japan and other countries
- ctDNA clearance data linked to longer-term efficacy will be presented at ASCO 2026 on June 2, 2026
- Original PDUFA date was not disclosed; new date not specified
Financial Impact
Camizestrant targets a US addressable population of ~37,000 patients annually in 1st-line HR+/HER2- metastatic breast cancer with ESR1 mutations. Launch delay could affect peak sales estimates, though no specific revenue figures were provided.
Risk Factors
- Extended review raises risk of Complete Response Letter (CRL) if additional data do not satisfy FDA concerns
- FDA's April ODAC split vote signals unresolved efficacy/benefit questions
- Competitive landscape (oral SERDs from Roche, Sanofi, etc.) continues to evolve during delay
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005381 |
| Document: 0001654954-26-005381-index-headers.html | 0001654954-26-005381 |
| Document: 0001654954-26-005381-index.html | 0001654954-26-005381 |
| Document: 0001654954-26-005381.txt | 0001654954-26-005381 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 6-K | $161.85 $168.37 | ▲ +4.03% | ▲ +1.90% | $157.02 (−2.98%) |
Sep 14, 2026 18d ago | 6-K | $163.78 $168.10 | ▼ −2.64% | ▼ −2.53% | $157.02 (+4.13%) |
Sep 8, 2026 24d ago | 6-K | $160.04 $161.85 | ▲ +1.13% | ▲ +2.25% | $157.02 (−1.89%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.22 $156.94 | ▼ −3.25% | ▼ −3.33% | $157.02 (−3.20%) |
Sep 1, 2026 4w ago | 6-K | $162.47 $156.94 | ▼ −3.40% | ▼ −3.49% | $157.02 (−3.35%) |
Aug 31, 2026 4w ago | Court Ruling | $162.13 $159.95 | ▲ +1.34% | ▲ +1.20% | $157.02 (+3.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access